Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy
Authors:
- Anna EeldeAEAnna Eelde
- Anna ÅgrenAÅAnna Ågren
- Sam SchulmanSSSam Schulman
- Margareta HolmströmMHMargareta Holmström
- 1 February 2012
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 129 (2) , 146-151
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Optimal Timing of Resumption of Warfarin After Intracranial HemorrhageStroke, 2010
- Safety of Recombinant Activated Factor VII in Randomized Clinical TrialsNew England Journal of Medicine, 2010
- Hemorrhagic Complications of Anticoagulant and Thrombolytic TreatmentChest, 2008
- What Is the Evidence for the Off-label Use of Recombinant Factor VIIa (rFVIIa) in the Acute Reversal of Warfarin?Hematology-American Society Hematology Education Program, 2008
- Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFPNeurology, 2006
- Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant TherapyStroke, 2006
- Transfusion‐related acute lung injury (TRALI): a serious adverse event of blood transfusionVox Sanguinis, 2005
- Warfarin, hematoma expansion, and outcome of intracerebral hemorrhageNeurology, 2004
- Care of Patients Receiving Long-Term Anticoagulant TherapyNew England Journal of Medicine, 2003
- Safety of Discontinuation of Anticoagulation in Patients With Intracranial Hemorrhage at High Thromboembolic RiskArchives of Neurology, 2000